- Trials with a EudraCT protocol (193)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
193 result(s) found for: Dementia praecox.
Displaying page 1 of 10.
| EudraCT Number: 2013-001315-71 | Sponsor Protocol Number: DPSANARI2012 | Start Date*: 2013-10-17 | |||||||||||
| Sponsor Name:Mercedes Zumarraga Ortiz | |||||||||||||
| Full Title: Dopaminergic genotype of schizophrenic patients and the benefit of adjunctive aripiprazole to risperidone treatment. The effect on hormonal and metabolic measures | |||||||||||||
| Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-004461-15 | Sponsor Protocol Number: PML0055 | Start Date*: 2005-04-05 | |||||||||||
| Sponsor Name:SANOFI-SYNTHELABO | |||||||||||||
| Full Title: SOLIAN solution in the acute setting | |||||||||||||
| Medical condition: Acute schizophrenia episode | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-000707-18 | Sponsor Protocol Number: 10206 | Start Date*: 2004-09-28 | |||||||||||
| Sponsor Name:LUNDBECK ITALIA | |||||||||||||
| Full Title: A 40-week open, flexible dose, extension study of bifeprunox in patients with schizophrenia. | |||||||||||||
| Medical condition: Long-term schizophrenia treatment | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-006636-22 | Sponsor Protocol Number: HA-1-2006 | Start Date*: 2007-04-05 | |||||||||||
| Sponsor Name:Jesper Ekelund | |||||||||||||
| Full Title: Histamiini H2 salpaus liitännäishoitona puutteellisen hoitovasteen skitsofreniassa | |||||||||||||
| Medical condition: Skitsofreniapotilaat joiden hoitovaste on puutteellinen. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-001441-26 | Sponsor Protocol Number: 12450A | Start Date*: 2009-04-01 | ||||||||||||||||
| Sponsor Name:H. Lundbeck A/S | ||||||||||||||||||
| Full Title: A randomised, double-blind, parallel-group, fixed dose study exploring the efficacy and safety of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia. | ||||||||||||||||||
| Medical condition: Lu AE58054 is under development by H.Lundbeck A/S as an anti-psychotic in the treatment of schizophrenia | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) DE (Completed) BE (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2015-003373-15 | Sponsor Protocol Number: ALK3831-A305 | Start Date*: 2016-04-25 | |||||||||||
| Sponsor Name:Alkermes Inc | |||||||||||||
| Full Title: A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects with Acute Exacerbation of Schizophrenia | |||||||||||||
| Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) HU (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-003880-13 | Sponsor Protocol Number: ALK3831-A306 | Start Date*: 2016-04-25 | |||||||||||
| Sponsor Name:Alkermes Inc | |||||||||||||
| Full Title: A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | |||||||||||||
| Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) HU (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-003996-20 | Sponsor Protocol Number: ALK9072-003EXT | Start Date*: 2013-03-28 | |||||||||||||||||||||
| Sponsor Name:Alkermes, Inc. | |||||||||||||||||||||||
| Full Title: A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects with Stable Schizophrenia | |||||||||||||||||||||||
| Medical condition: stable schizophrenia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BG (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2005-002169-35 | Sponsor Protocol Number: 25544 | Start Date*: 2005-12-27 | |||||||||||
| Sponsor Name:NV Organon | |||||||||||||
| Full Title: A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the safety and Efficacy of Asenapine With Olanzapine in Subjects who Completed Protocol 25543 | |||||||||||||
| Medical condition: Schizophrenia with predominant, persistent negative symptoms | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) GB (Completed) ES (Completed) CZ (Completed) DE (Completed) HU (Completed) SE (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-012568-14 | Sponsor Protocol Number: 331-08-210 | Start Date*: 2009-11-18 | |||||||||||
| Sponsor Name:Otsuka Pharmaceutical Development & Commercialization | |||||||||||||
| Full Title: A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Monotherapy in Adult Patients with Schizophrenia | |||||||||||||
| Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003834-34 | Sponsor Protocol Number: NBI-1065844-CIAS2023 | Start Date*: 2023-02-23 | |||||||||||
| Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizop... | |||||||||||||
| Medical condition: Cognitive Impairment Associated With Schizophrenia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-005513-40 | Sponsor Protocol Number: 2012-005513-40 | Start Date*: 2013-05-28 | |||||||||||
| Sponsor Name:HYKS Psykiatrikeskus | |||||||||||||
| Full Title: Histamine H2 antagonism as adjuvant therapy in treatment resistant schizophrenia | |||||||||||||
| Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Prematurely Ended) FI (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-005499-34 | Sponsor Protocol Number: 11352A | Start Date*: 2007-03-13 | |||||||||||
| Sponsor Name:H. Lundbeck A/S | |||||||||||||
| Full Title: A double-blind, randomised, placebo-controlled, quetiapine-referenced, multicentre study of the long-term bifeprunox efficacy, safety and tolerability in patiens with stable schizophrenia | |||||||||||||
| Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-000418-13 | Sponsor Protocol Number: M10-855 | Start Date*: 2012-12-21 | |||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
| Full Title: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) | |||||||||||||
| Medical condition: Cognitive Deficits in Schizophrenia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-002245-20 | Sponsor Protocol Number: EICAS | Start Date*: 2008-08-15 | |||||||||||
| Sponsor Name:Zentralinstitut für Seelische Gesundheit Mannheim | |||||||||||||
| Full Title: Evaluation of potential central glucoregulatory compounds to treat/ameliorate the symptoms of schizophrenia: a proof-of-concept study in healthy volunteers | |||||||||||||
| Medical condition: Basic ressearch on schizophrenia. This is a proof-of-concept trial. The hypothesis is that substances that regulate the central glucose utilisation might ameliorate symptoms of schizophrenic psyc... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-002838-10 | Sponsor Protocol Number: FIS-SJD-SSM-1 | Start Date*: 2008-07-27 | |||||||||||
| Sponsor Name:SANT JOAN DE DEU - SSM | |||||||||||||
| Full Title: Ensayo doble ciego controlado con placebo de la eficacia de reboxetina y citalopram como tratamiento coadyuvante de los antipsicóticos de segunda generación en el tratamiento de los síntomas negati... | |||||||||||||
| Medical condition: SINTOMAS NEGATIVOS EN ESQUIZOFRENIA | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-013020-23 | Sponsor Protocol Number: RAA09-002 | Start Date*: 2010-03-23 | |||||||||||
| Sponsor Name:King's College London | |||||||||||||
| Full Title: A Pilot study of cognitive enhancer and cognitive training combination – Testing a therapeutic paradigm for cognitive impairment in schizophrenia | |||||||||||||
| Medical condition: Cognitive impairment associated with schizophrenia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002520-82 | Sponsor Protocol Number: CLO-MEAS | Start Date*: 2015-08-27 | |||||||||||
| Sponsor Name:Prof., dr. med. Anders Fink-Jensen | |||||||||||||
| Full Title: The significance of deviation in time from the 12-hour standard serum-clozapine monitoring | |||||||||||||
| Medical condition: Treatment-resistant schizophrenia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-007538-21 | Sponsor Protocol Number: CYR-101C01 | Start Date*: 2008-04-22 | |||||||||||
| Sponsor Name:CYRENAIC | |||||||||||||
| Full Title: A Multi-center, Inpatient and ambulatory, Phase 2, Double-blind, Randomised, Placebo-controlled Proof of Concept Study of CYR-101 in Patients with DSM-IV Schizophrenia | |||||||||||||
| Medical condition: Diagnosis of Schizophrenia in Male or female patients, as defined in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revised (DSM-IV TR, APA 2000) and confirmed by the St... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-006738-85 | Sponsor Protocol Number: QGUY/2008/FazaClo/-01 | Start Date*: 2008-11-21 | |||||||||||
| Sponsor Name:Azur Pharma, Ltd. | |||||||||||||
| Full Title: A Single Dose, Open-Label, Randomized, Two-Way Crossover Food Effect Study Comparing 12.5 mg FazaClo™ (clozapine) ODT under Fasted and Fed Conditions in Healthy Male Volunteers. | |||||||||||||
| Medical condition: Resistant schizophrenia in patients | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.